Dendrite Advances Pharmaceutical Relationship Marketing with Optas Acquisition.

BEDMINSTER, N.J. -- Dendrite International, Inc. (NASDAQ: DRTE) a leading provider of sales, marketing and clinical solutions for the pharmaceutical industry, today announced the acquisition of Optas, Inc., the industry's premier provider of privacy-safe, relationship marketing solutions for patients and physicians aimed at improving patient acquisition and therapeutic compliance by providing higher levels of support services.

The resulting integrated patient and prescriber-based marketing programs enable pharmaceutical companies to reach physicians and consenting patients with consistent messages while maintaining adherence with federal and state regulations surrounding privacy (e.g., HIPAA - the Health Insurance Portability and Accountability Act).

"This transaction is instrumental to Dendrite's integrated marketing and sales solutions strategy," said Paul Zaffaroni, Dendrite President and COO. "We are already the leading provider of technology and marketing solutions targeted at the physician community. With Optas' integrated doctor and patient-based marketing capabilities, we are now able to integrate patient support for our pharmaceutical customers."

Dendrite and Optas are already deployed together in a large pharmaceutical company where Optas enables physicians to direct patients into an education program, and Dendrite provides a personalized patient medical support center where patients speak to medical professionals who complement and support the prescribing doctor's own initiatives. Both elements are orchestrated through Optas' campaign management tool and embrace ongoing two-way communications with patients through opt-in protocols.

"The opportunity to join Dendrite, the market leader, with its long-term reputation and global footprint, is extremely exciting," said Stephen Smith, CEO of Optas. "The pharmaceutical industry is experiencing rapid change in the way sales and marketing initiatives are executed. Our combined offering will enable pharma companies to reach physicians and patients with consistent messaging and campaigns driven by deep patient and physician knowledge. This will set the standard for how sales and marketing are conducted in the industry for years to come."

The Optas acquisition is valued at $12 million and will be funded by cash. Optas, formerly a private company headquartered in Woburn, MA, will be branded as Optas: a Division of Dendrite International.

About Dendrite

Founded in 1986, Dendrite International (NASDAQ: DRTE) provides diversified sales, marketing, clinical and compliance solutions to the global life sciences and pharmaceutical industry. With clients in more than 50 countries, including the world's top 20 pharmaceutical companies, Dendrite strives to be the first source for expert promotional and sales effectiveness solutions. For more information, please visit www.dendrite.com.

About Optas

Founded in 1997, Optas is the leading provider of privacy-safe database marketing software and services that allow pharmaceutical companies and health systems to communicate more effectively with customers. Marketers and their agencies use Optas solutions to improve acquisition and loyalty of their customers. Optas provides rapid deployment and a high return on marketing investment for its clients because of its customizable support of business processes. For more information about Optas, visit www.optas.com.

Note: Dendrite and Optas are registered trademarks of Dendrite International, Inc. and/or its subsidiaries

This document may contain forward-looking statements that may be identified by such forward-looking terminology as "expect," "believe," "anticipate," "will," "intend," "plan," "target," "outlook," "guidance," and similar statements or variations. Such forward-looking statements are based on our current expectations, estimates, assumptions and projections and involve significant risks and uncertainties, including risks which may result from our dependence on the pharmaceutical industry; fluctuations in quarterly revenues due to lengthy sales and implementation cycles for certain of our solutions; our fixed expenses in relation to fluctuating revenues and variations in customers' budget cycles; dependence on certain major customers; changes in demand for our products and services attributable to any weakness experienced in the economy or mergers, acquisitions and consolidations in the pharmaceutical industry; successful and timely development and introduction of new products and versions; rapid technological changes; increased competition; international operations; integrating the entities we acquire; our ability to effectively manage our growth; the protection of our proprietary technology; our ability to compete in the Internet-related products and services market; the continued demand for Internet-related products and services; the ability of our third party vendors to respond to technological change; our ability to maintain our relationships with third-party vendors; less favorable than anticipated results from strategic relationships; dependence of data solutions on strategic relationships; events which may affect the U.S. and world economies; and catastrophic events which could negatively affect our information technology infrastructure. Other important factors that should be reviewed and carefully considered are included in the company's 10-K, 10-Qs, and other reports filed with the SEC. Actual results may differ materially. The company assumes no obligation for updating any such forward-looking statements to reflect actual results, changes in assumptions or other changes affecting such forward-looking statements.